Company Filing History:
Years Active: 1996-2016
Title: The Innovative Contributions of Robert E. Humphreys in Vaccine Development
Introduction
Robert E. Humphreys, an accomplished inventor based in Acton, MA, has made significant strides in the field of vaccine development. With a total of 14 patents to his name, Humphreys has focused on enhancing immunological responses through innovative hybrid polypeptides and vaccine constructs.
Latest Patents
Among his latest patents, Humphreys has developed the II-key/antigenic epitope hybrid peptide vaccines. This groundbreaking invention incorporates an antigen presentation enhancing hybrid polypeptide, consisting of an N-terminal element with specific amino acid residues, a flexible chain chemical structure, and a C-terminal element featuring an antigenic epitope. These components work together to improve the binding to MHC class II molecules, thereby enhancing antigen presentation. Another notable patent is the Ii-key/HER-2/neu hybrid cancer vaccine, which provides methods and compositions for treating cancer characterized by the expression of Her-2/neu. This innovative hybrid construct aims to stimulate an immune response against the native Her-2/neu protein and has potential applications in breast cancer treatment.
Career Highlights
Robert E. Humphreys has collaborated with prominent organizations such as Antigen Express, Inc. and the University of Massachusetts. His work focuses on advancing therapeutic techniques in the realm of immunology and cancer treatment. He has developed creative solutions that demonstrate significant scientific advancements in vaccine efficacy.
Collaborations
Throughout his career, Humphreys has worked alongside noteworthy individuals, including Minzhen Xu and Sharlene Adams. His collaborative spirit has led to the improvement of existing technologies and the creation of novel approaches in vaccine development.
Conclusion
The contributions of Robert E. Humphreys exemplify innovation in the fields of immunology and cancer treatment. His patents, focusing on hybrid peptide vaccines, have the potential to transform therapeutic strategies and improve patient outcomes. Humphreys' work is a testament to the importance of invention in addressing complex medical challenges.